SEGMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2020

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	For the six Months Ended April 30,
	2020		2019
Net loss:
CAR-T Therapeutics	$	(1,125,363)	$	(3,517,219)
Cancer Vaccines		(365,867)		-
Anti-Viral Therapeutics		(309,504)		-
Cancer Diagnostics		(3,469,673)		(3,052,355)
Patent Licensing		(4,158)		(971,969)
Total	$	(5,274,565)	$	(7,541,543)
Total operating costs and expenses	$	5,300,006	$	7,826,962
Less non-cash share-based compensation		(2,131,420)		(4,071,614)
Operating costs and expenses excluding     non-cash share-based compensation	$	3,168,586	$	3,755,348
Operating costs and expenses excluding non-cash     share based compensation expense:
CAR-T Therapeutics	$	570,163	$	1,245,681
Cancer Vaccines		165,329		-
Anti-Viral Therapeutics		221,018		-
Cancer Diagnostics		2,208,813		1,417,967
Patent Licensing		3,263		1,091,700
Total	$	3,168,586	$	3,755,348

	For the Three Months Ended April 30,
	2020		2019
Net loss:
CAR-T Therapeutics	$	(495,030)	$	(1,029,934)
Cancer Vaccines		(170,271)		-
Anti-Viral Therapeutics		(309,504)		-
Cancer Diagnostics		(1,679,027)		(1,249,001)
Patent Licensing		(4,158)		(296,999)
Total	$	(2,657,990)	$	(2,574,934)
Total operating costs and expenses	$	2,670,137	$	2,843,234
Less non-cash share-based compensation		(1,110,086)		(1,321,450)
Operating costs and expenses excluding     non-cash share-based compensation	$	1,560,051	$	1,521,784
Operating costs and expenses excluding non-cash     share based compensation expense:
CAR-T Therapeutics	$	223,822	$	444,890
Cancer Vaccines		67,059		-
Anti-Viral Therapeutics		221,018		-
Cancer Diagnostics		1,044,889		658,433
Patent Licensing		3,263		418,461
Total	$	1,560,051	$	1,521,784

	April 30, 2020		October 31, 2019
Total assets:
CAR-T Therapeutics	$	1,011,316	$	2,382,460
Cancer Vaccines		287,831		489,881
Anti-Viral Therapeutics		384,326		-
Cancer Diagnostics		4,089,496		2,921,784
Patent Licensing		151,926		499,568
Total	$	5,924,895	$	6,293,693